Home|Journals|Articles by Year|Audio Abstracts
 

Review Article

Ann Med Res. 2013; 20(2): 185-191


Angiotensin II Type 2 Receptor (AT2) and Agonists in Cardiovascular System

Hakan Parlakpınar1, Mustafa Sağır1, Mehmet Hamdi Örüm2

.




Abstract


Angiotensin II is an effector peptide of the renin angiotensin system. Angiotensin II which regulates cellular growth in response to developmental, physiological, and pathological processes has two main receptor subtypes which are the AT1 and AT2 receptor. It is well established that angiotensin II has an important role in regulating cardiovascular hemodynamics and structure. Most of the known effects of angiotensin II in cardiovascular system are attributable to the AT1 receptor, and it has been a drug target in cardiovascular disease for many years. On the other hand, less was known about the AT2 receptor and it remained only an academic interest. This circumstance has changed with the synthesis of a first non-peptide AT2 receptor agonist, compound 21. The studies using compound 21 indicated tissue protective effects and functional improvement after myocardial infarction. Then, the research has continued to reveal AT2 receptor mediated effects in cardiovascular system. Herein, we will discuss the role of the peptide (CGP42112A, novokinin) and the non-peptide (compound 21) AT2 receptor agonists in the cardiovascular system.

Key Words: Angiotensin II; AT2 Agonist; Cardiovascular System.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.